These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 31781564)

  • 1. Efficiency of Therapeutic Plasma-Exchange in Acute Interstitial Lung Disease, Associated With Polymyositis/Dermatomyositis Resistant to Glucocorticoids and Immunosuppressive Drugs: A Retrospective Study.
    Ning Y; Yang G; Sun Y; Chen S; Liu Y; Shi G
    Front Med (Lausanne); 2019; 6():239. PubMed ID: 31781564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of Myositis-Associated Interstitial Lung Disease.
    Fujisawa T
    Medicina (Kaunas); 2021 Apr; 57(4):. PubMed ID: 33916864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Serum Chitotriosidase Level in Anti-MDA5 Antibody-positive Dermatomyositis-associated Interstitial Lung Disease.
    Fujisawa T; Hozumi H; Yasui H; Suzuki Y; Karayama M; Furuhashi K; Enomoto N; Nakamura Y; Inui N; Suda T
    J Rheumatol; 2019 Aug; 46(8):935-942. PubMed ID: 31092718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The clinical significance of myositis-specific antibodies in polymyositis/dermatomyositis associated interstitial lung diseases].
    Xie MM; Yan X; Li H; Ding JJ; Gui XH; Liu Y; Wang YS; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2018 Aug; 41(8):616-621. PubMed ID: 30138971
    [No Abstract]   [Full Text] [Related]  

  • 6. Predictive factors for long-term outcome in polymyositis/dermatomyositis-associated interstitial lung diseases.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Nakamura Y; Inui N; Nakashima R; Imura Y; Mimori T; Suda T
    Respir Investig; 2017 Mar; 55(2):130-137. PubMed ID: 28274528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L; Wang H; Wang Q; Wu C; Liu C; Zhang Y; Cheng L; Zeng X; Zhang F; Li Y
    J Neurol Sci; 2019 Feb; 397():123-128. PubMed ID: 30616054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study.
    Ye S; Chen XX; Lu XY; Wu MF; Deng Y; Huang WQ; Guo Q; Yang CD; Gu YY; Bao CD; Chen SL
    Clin Rheumatol; 2007 Oct; 26(10):1647-54. PubMed ID: 17308858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of interstitial lung disease in polymyositis and dermatomyositis: A meta-analysis from 2000 to 2020.
    Sun KY; Fan Y; Wang YX; Zhong YJ; Wang GF
    Semin Arthritis Rheum; 2021 Feb; 51(1):175-191. PubMed ID: 33383294
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H; Katsumata Y; Nishino A; Hirahara S; Kawaguchi Y; Kuwana M; Yamanaka H
    J Rheumatol; 2018 Jul; 45(7):947-955. PubMed ID: 29657141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive factors and unfavourable prognostic factors of interstitial lung disease in patients with polymyositis or dermatomyositis: a retrospective study.
    Ji SY; Zeng FQ; Guo Q; Tan GZ; Tang HF; Luo YJ; Tang ZQ; Han YF
    Chin Med J (Engl); 2010 Mar; 123(5):517-22. PubMed ID: 20367973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of HRCT in myositis-associated interstitial lung disease.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Aihara K; Ikezoe K; Watanabe K; Taguchi Y; Hatta K; Oga T; Chin K; Nagai S; Mimori T; Mishima M
    Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors for myositis-associated interstitial lung disease.
    Fujisawa T; Hozumi H; Kono M; Enomoto N; Hashimoto D; Nakamura Y; Inui N; Yokomura K; Koshimizu N; Toyoshima M; Shirai T; Yasuda K; Hayakawa H; Suda T
    PLoS One; 2014; 9(6):e98824. PubMed ID: 24905449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T; Kaneko H; Kawaguchi Y; Hanaoka M; Kataoka S; Kuwana M; Takagi K; Ichida H; Katsumata Y; Ota Y; Kawasumi H; Yamanaka H
    Rheumatology (Oxford); 2014 Dec; 53(12):2196-203. PubMed ID: 24970922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interstitial lung disease in polymyositis and dermatomyositis.
    Marie I; Hachulla E; Chérin P; Dominique S; Hatron PY; Hellot MF; Devulder B; Herson S; Levesque H; Courtois H
    Arthritis Rheum; 2002 Dec; 47(6):614-22. PubMed ID: 12522835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F; Li S; Wang T; Shi J; Wang G
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical value of myositis antibodies in patients with connective tissue disease-associated interstitial lung diseases].
    Xie MM; Zou RY; Li Y; Liu Y; Chen LL; Liu XQ; Zhao Q; Ding JJ; Chen ZY; Cai HR
    Zhonghua Jie He He Hu Xi Za Zhi; 2019 Oct; 42(10):765-770. PubMed ID: 31594111
    [No Abstract]   [Full Text] [Related]  

  • 18. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.
    Ikeda S; Arita M; Misaki K; Mishima S; Takaiwa T; Nishiyama A; Ito A; Furuta K; Yokoyama T; Tokioka F; Noyama M; Yoshioka H; Ishida T
    Springerplus; 2015; 4():240. PubMed ID: 26101728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in clinical features and prognosis of interstitial lung diseases between polymyositis and dermatomyositis.
    Fujisawa T; Suda T; Nakamura Y; Enomoto N; Ide K; Toyoshima M; Uchiyama H; Tamura R; Ida M; Yagi T; Yasuda K; Genma H; Hayakawa H; Chida K; Nakamura H
    J Rheumatol; 2005 Jan; 32(1):58-64. PubMed ID: 15630726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
    Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
    Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.